Children's Oncology Group's 2023 blueprint for research: Rare tumors.
The Children's Oncology Group (COG) Rare Tumor Committee includes the Infrequent Tumor and Retinoblastoma subcommittees, encompassing a wide range of extracranial solid tumors that do not fall within
APA
Schultz KAP, Chintagumpala M, et al. (2023). Children's Oncology Group's 2023 blueprint for research: Rare tumors.. Pediatric blood & cancer, 70 Suppl 6(Suppl 6), e30574. https://doi.org/10.1002/pbc.30574
MLA
Schultz KAP, et al.. "Children's Oncology Group's 2023 blueprint for research: Rare tumors.." Pediatric blood & cancer, vol. 70 Suppl 6, no. Suppl 6, 2023, pp. e30574.
PMID
37458616
Abstract
The Children's Oncology Group (COG) Rare Tumor Committee includes the Infrequent Tumor and Retinoblastoma subcommittees, encompassing a wide range of extracranial solid tumors that do not fall within another COG disease committee. Current therapeutic trial development focuses on nasopharyngeal carcinoma, adrenocortical carcinoma, pleuropulmonary blastoma, colorectal carcinoma, melanoma, and thyroid carcinoma. Given the rarity of these tumors, novel strategies and international collaborative efforts are necessary to advance research and improve outcomes.
MeSH Terms
Child; Humans; Medical Oncology; Thyroid Neoplasms; Adrenal Cortex Neoplasms; Nasopharyngeal Neoplasms; Retinal Neoplasms